Replies to post #170148 on Cytodyn Inc (CYDY)

[ClosetInvestor]

“Many shareholders have a lot to complain about with Nader. Is it possible that Nader has learned a lesson as demonstrated by no PR about the Brazil FDA Trial??”

There’s nothing to update about the Brazil trial, yet. The document that moneycrew posted isn’t trial approval, it’s the new common denominations list (DCB). The DCB is update annually and is used to standardize the nomenclature of drugs for ANVISA for trials, registration, etc. This is similar to earlier this year, when the U.S. government added leronlimab (and other drugs) to a list (can’t recall the name of that list).

[that_little_voice]

It is a proven statistics that any common that does a reverse drops 8-15% where a forward split adds 12-17%. My question Mr. Ops is what would a reverse split be the first thing a new CEO would do? The current CEO is the one that issued hundreds of millions of shares and allowing the stock price to fall back to $1 with fake and empty promises of progress. If the 13D group can bring in a real name CEO with a proven drug approval background, you still think the market will hammer the price? I think it would actually raise the share price.

However, this is all a moot point. Nobody is coming to rescue the day for CYDY because LL is not effective in any of the trials run nor will it ever. The shareholders live by Nader and will die by Nader.

Last point, CEO won't spend their personal money in a proxy battle per say. However, they could use their personal money to buy shares. If Nader truly believes this is triple digits, what other investments is he looking at that is getting his personal investment dollars? $1.90 is an awful good entry for a stock that will be at $100. Can you agree?